Biocryst Pharma Inc (BCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 89,937 | 104,923 | 112,447 | 306,239 | 507,734 |
| Marketable Securities | 185,011 | 216,137 | 278,344 | 119,543 | 3,212 |
| Receivables | 106,818 | 79,069 | 56,950 | 50,599 | 29,413 |
| Inventories | 5,398 | 8,087 | 28,683 | 27,533 | 15,791 |
| TOTAL | $404,346 | $421,968 | $495,966 | $516,500 | $566,136 |
| Non-Current Assets | |||||
| PPE Net | 8,783 | 7,777 | 7,910 | 8,617 | 8,714 |
| Investments And Advances | 61,164 | 20,323 | 0 | 18,077 | 6,829 |
| Other Non-Current Assets | 39,865 | 40,352 | 13,084 | 6,806 | 6,472 |
| TOTAL | $109,812 | $68,452 | $20,994 | $33,500 | $22,015 |
| Total Assets | $514,158 | $490,420 | $516,960 | $550,000 | $588,151 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 52,198 | 32,676 | 23,565 | N/A | N/A |
| Accounts payable and accrued liabilities | 15,826 | 11,644 | 20,893 | 14,356 | 27,808 |
| Accrued Expenses | 126,413 | 113,292 | 102,882 | 87,565 | 72,670 |
| TOTAL | $196,066 | $160,384 | $149,988 | $105,514 | $103,718 |
| Non-Current Liabilities | |||||
| Long Term Debt | 427,233 | 795,922 | 811,265 | 733,279 | 585,457 |
| Deferred Revenues | N/A | N/A | N/A | 1,224 | 1,421 |
| Other Non-Current Liabilities | 8,571 | 7,924 | 8,390 | 4,027 | 0 |
| TOTAL | $437,245 | $805,970 | $822,500 | $739,083 | $591,419 |
| Total Liabilities | $633,311 | $966,354 | $972,488 | $844,597 | $695,137 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 250,801 | 208,960 | 206,150 | 188,451 | 184,662 |
| Common Shares | 2,131 | 2,085 | 2,058 | 1,879 | 1,843 |
| Retained earnings | -1,506,179 | -1,770,040 | -1,681,159 | -1,454,620 | -1,207,504 |
| Other shareholders' equity | 38 | 921 | 1,337 | 26 | 177 |
| TOTAL | $-119,153 | $-475,934 | $-455,528 | $-294,597 | $-106,986 |
| Total Liabilities And Equity | $514,158 | $490,420 | $516,960 | $550,000 | $588,151 |